MIRA
INFORM REPORT
|
Report Date : |
05.02.2008 |
IDENTIFICATION
DETAILS
|
Name : |
JAZEERA PHARMACEUTICAL INDUSTRIES |
|
|
|
|
Registered Office : |
New Akareya Building, Salah El Din Street, PO Box 106229, Riyadh 11666 |
|
|
|
|
Country : |
Saudi Arabia |
|
|
|
|
Date of Incorporation : |
1997 |
|
|
|
|
Com. Reg. No.: |
1010124373, Riyadh |
|
|
|
|
Legal Form : |
Limited Liability Company |
|
|
|
|
Line of Business : |
Manufacturers of Pharmaceutical Preparations and Medical
Products |
RATING &
COMMENTS
|
MIRA’s Rating : |
A |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
Maximum Credit Limit : |
US$ 750,000 |
|
|
|
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
SUMMARY
Company Name : JAZEERA PHARMACEUTICAL INDUSTRIES
Country of Origin : Saudi Arabia
Legal Form : Limited Liability Company
Registration Date : 1997
Commercial Registration Number : 1010124373, Riyadh
Membership Number : 70256
Issued Capital : SR 50,000,000
Paid up Capital : SR 50,000,000
Total Workforce : 300
Line of Business : Manufacturers of pharmaceutical preparations and medical products.
Financial Condition : Undetermined
Payments : Nothing detrimental uncovered
COMPANY NAME
JAZEERA PHARMACEUTICAL INDUSTRIES
ADDRESS
Registered & Physical Address
Building : New Akareya Building
Street :
Salah El Din Street
PO Box : 106229
Town : Riyadh 11666
Country : Saudi Arabia
Telephone : (966-1) 4980158
/ 4980162 / 4980170 / 4788221 / 2830245
Facsimile : (966-1)
4980187 / 4761097
Email : admin@japi.com.sa
Premises
Subject operates from a large suite of offices that are rented and
located in the Industrial Area of Riyadh.
Branch Office (s)
Location Description
· 3rd
Industrial Zone Owned
factory premises covering an
South of Riyadh area
of 15,000 square metres
KEY PRINCIPALS
· Saud Ibrahim Al
Jamaz Chairman
· Dr Ishaaq Al
Hajeri General
Manager
· Khader Al Jerwan Commercial
Manager
· Khalid Al Hanbali Production
Manager
LEGAL FORM & OWNERS
Date of
Establishment : 1997
Legal Form : Limited Liability
Company
Commercial Reg.
No. : 1010124373, Riyadh
Membership No. : 70256
Issued Capital : SR 50,000,000
Paid up Capital : SR 50,000,000
Name of Shareholder (s)
· Al Hikma
Pharmaceuticals
Amman
Jordan
LINE OF BUSINESS
Operations : Engaged in the manufacture of pharmaceutical
preparations and medical products.
Subject has a product range comprising more
than 110 registered products, specialising in
therapeutic areas, such as Anti-infectives, Musculo-skeletal, Cardiovascular,
Alimentary, Respiratory, Dermatology, Genito-urinary.
Production Capacity: 220 million
capsules per annum
690
million tablets
27
million suppositories
16
million pouches
54
million liquid and powder-filled bottles
Import Countries : Europe, the Far East and the United States of
America.
International Suppliers :
· Danippon
Pharmaceutical Co Ltd Japan
· Tanabe Seiyaku Co
Ltd Japan
Subject has a workforce of approximately 300 employees.
FINANCIAL HIGHLIGHTS
Companies registered in Saudi Arabia are not legally required to make
their accounts public and no financial information was released by the company
or submitted by outside sources.
BANKERS
·
Riyad Bank
King Abdul Aziz Road
PO Box : 22622
Riyadh 11416
Tel : (966-1) 4013030
·
Arab National Bank (ANB)
King Faisal Street
PO Box : 56921
Riyadh 11564
Tel : (966-1)
4029000
Fax : (966-1)
4027747
PAYMENT HISTORY
No complaints regarding subject’s payments have been reported.
GENERAL COMMENTS
Established in 1997, subject is involved in the manufacture of
pharmaceutical preparations and medical products.
During the course of this investigation nothing detrimental was
uncovered regarding subject’s operating history or the manner in which payments
are fulfilled. As such the company is considered to be a fair trade risk.
Maximum suggested credit figure: US$ 750,000
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)